Ampicillin/sulbactam is a beta-lactam/beta lactamase inhibitor combination antibiotic.
It has activity against MSSA, streptococci, enterococci, and anaerobes. It also has activity against enteric Gram-negative organisms.
However, an increasing number of E. coli and Proteus spp. are now resistant.
Because of this, its use for empiric treatment of intraabdominal infections is no longer advised unless pathogen susceptibilities are known.
Antibiogram data are derived from Jan 1, 2016 to July 26, 2016.
Ampicillin and Ampicillin-sulbactam testing were discontinued on July 26, 2016.